

REMARKS


In the subject communication, the Examiner indicated that there were drawing deficiencies, stating that Figure 10B is listed in the Brief Description of the Drawings, but is not contained in the Drawings.

Applicants believe that the subject communication was sent in error. Applicants have reviewed the file and find that a Drawing labeled Fig. 10B (copy enclosed) is indeed contained in the application documents. Applicants also enclose a copy of page 10 of the specification, which provides a Brief Description of the Drawings listing Fig. 10B.

Enclosed also is a copy of the referenced office communication.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/UTSC:550US.

Respectfully submitted,


David L. Parker
Reg. No. 32,165
Attorney for Applicants

Date: June 27, 2007

10/12




FIG. 10A




FIG. 10B

accumulation of p53 protein is only observed in nuclei isolated from irradiated LNCaP control cells.

FIG. 10B: Confocal microscopic analysis of p53 subcellular localization following irradiation. LNCaP control (left) and LNCaP-bcl-2 (right) cells were irradiated with 20 Gy, fixed after 4 hours, and p53 protein imaged by scanning confocal laser microscopy. Nuclear localization of p53 protein is only observed in LNCaP control cells.

FIG. 10C: Bcl-2 inhibition of transcriptional activation by wt-p53. NIH3T3 cells were transfected with the effector wild type (P53 WT) or mutant p53 (P53 MUT) plasmid (10 µg), reporter plasmid P2mdm2-Luc (4 µg) and β-galactosidase (βgal) expression plasmid (3µg) with or without the bcl-2 expression vector (BCL-2) (20 µg) using the calcium-phosphate method. Co-transfection with empty effector vector (VECTOR) served as a negative control. Data represent the fold increase in luciferase activity. Bcl-2 significantly inhibited the ability of wild type p53 protein to transactivate the mdm2 promoter (* $p \leq 0.02$).

FIG. 11A & FIG. 11B: Downregulation of bcl-2 in RKO colon cancer cells by antisense oligonucleotides and localization of p53.

FIG. 11A: Selective downregulation of bcl-2 protein in RKO colon cancer cells. Western blotting of whole cell extracts (40 µg) were analyzed by immunoblotting for bcl-2 protein. A graphic representation of the relative amount of bcl-2 protein after normalization for protein loading is shown. Treatment with antisense bcl-2 oligonucleotides, but not control oligonucleotides or empty liposomes, resulted in a reduction in the amount of bcl-2 protein.

FIG. 11B: Confocal microscopy of p53 protein in irradiated RKO cells treated with control oligonucleotides (top) or antisense-bcl-2 oligonucleotides (bottom). Significant nuclear localization of p53 protein following irradiation is observed only in antisense-bcl-2 treated RKO cells.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/381,747	09/22/1999	MAR TORMO	UTSC:550---/IPAR	4363

7590 06/07/2007
FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue
Suite 2400
Austin, TX 78701

EXAMINER

CHONG, KIMBERLY

ART UNIT	PAPER NUMBER
----------	--------------

1635

MAIL DATE	DELIVERY MODE
-----------	---------------

06/07/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

FULBRIGHT & JAWORSKI, LLP
IPT DOCKETING
Docketed ☒ Not Req'd ☐ Confirmation ☐
Initials 1st JDS Initials 2nd RLH

JUN 14 2007

Attorney DLP
Docket No. A0-UTSC:550
Action Req'd _____ Date Due _____

1 MO RESP DUE (NO EXT) - LAST DAY
gen. Rem.

07/07/07
6/30/07



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

NOTICE OF DRAWING INCONSISTENCY WITH SPECIFICATION

The drawings filed 05-25-2007 have been received. However, an inconsistency exists between the drawings and the Brief Description of the Drawings in the specification.

Figure 10B is listed in the Brief Description of the Drawings in the specification but not contained in the Drawings.

Figures _____ are contained in the Drawings but not listed in the Brief Description of the Drawings in the specification.

Applicant is required to correct the above-noted inconsistency within a time period of **ONE MONTH or THIRTY (30) DAYS, whichever is longer**, from the mailing date of this Notice, or within the time remaining in the time period set forth in the Notice of Allowability (Form PTOL-37) to file corrected drawings, whichever is longer. **NO EXTENSION OF THIS TIME PERIOD MAY BE GRANTED UNDER EITHER 37 CFR 1.136 (a) OR (b)**

Failure to correct the above noted inconsistency will result in **abandonment** of the application.

The file will be held in the Publishing Division to await the correction of the inconsistency.

Return Corrected Drawings/Specification to:

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450

Alexandria, VA 22313-1450

Office of Patent Publication/Publishing Division
Customer Service: 703-308-6789
1-888-786-0101

FORM PTO-1631 (REV. 10-03)